NEW YORK, May 24, 2017 /PRNewswire/ --
One major component of the legal cannabis industry is the CBD market. CBD is the part
of the cannabis plant that doesn't have any psychotropic effects, and is usually used for
medical purposes opposed to recreational. Forbes reported that according to Matt Karnes
of Greenwave Advisors, "In terms of the CBD market size, I estimate an almost $3 billion
market by 2021. Right now there are 15 states that allow CBD only - this is in addition to
the 28 states plus DC that have legalized medical marijuana." The report indicates that
the CBD market has already been targeted by industry insiders. According to Headset
Research data, in Washington state alone there are over 800 CBD products in the
marketplace. ChineseInvestors.com, Inc. (OTC: CIIX), Eco Science Solutions, Inc. (OTC:
ESSI), Cannabis Sativa. Inc. (OTC: CBDS), Cara Therapeutics Inc. (NASDAQ: CARA), AXIM
Biotechnologies, Inc. (OTC: AXIM)
As for the whole legal cannabis market, Arcview Market Research forecasts that growth
will reaccelerate beginning in 2018, as adult-use sales ramp up in Canada, California, and
Massachusetts along with medical sales in Florida. That will grow the $6.7-billion market
of 2016 at a robust 27% CAGR to $22.6 billion in 2021. The biggest political win of the
U.S. election in 2016 came in California, where cannabis products are now legal for
medical and recreational purposes.
ChineseInvestors.com, Inc . (OTCQB: CIIX) earlier today announced that,
"Chinesehempoil.com Inc., established last month as a wholly-owned subsidiary of CIIX,
will officially launch its own premium hemp health product line 'OptHemp',", which will
include the Company's first private label product, OptHemp Ultra Premium Hemp Oil.
The OptHemp products will be available at http://www.ChineseHempOil.com , the
Company's official bi-lingual site. CIIX will use multiple sales channels to implement its
sales plan including online sales, retail sales and direct marketing. As part of its plan,
CIIX is close to completing construction on its first retail store, which will be among
the first retail stores to offer premium hemp-based products along with other health
products in San Gabriel, CA. The Company is expected to open the retail store this June in
an optimal location within one of the city's premier Chinese consumer districts.
"I am very pleased to announce the launch of our first premium OptHemp product," says
Warren Wang, Founder and CEO of CIIX. "Hemp oil is believed to have positive balancing
effects on the mind and body of persons using them."
OptHemp Ultra Premium Hemp Oil, the line's base level product, is extracted and
purified with raw materials from 100% organic farms in Colorado using a supercritical CO2
extraction technology. OptHemp products are GMO-free, making them attractive to consumers
concerned about product source and purity.
"We believe that the desire for better quality of life in the Chinese community,
coupled with fact that the aging population continues to grow, will lead to continued
growth in the alternative health sector and increased demand for natural hemp-based health
products," says Wang. "CIIX is confident that its OptHemp product line will lay a solid
foundation for the Company's entrance into the legal hemp industry and the alternative
health sector."
Eco Science Solutions, Inc. (OTCQB: ESSI) is a technology-focused company targeting
the health, wellness and alternative medicine industry. Recently, the company announced
that it has signed a Sponsorship, Content Development and Licensing agreement with Roaring
Lion Tours, Inc. to develop unique educational content that brings awareness and education
to the alternative medicine category. Roaring Lion Tour develops inspirational and
education content that further promotes the benefits of medical marijuana. "There is a
continuing need to bring awareness to the benefits of medical marijuana as a key category
in the alternative medical health industry," stated Jeff Taylor, Chief Executive Officer
of Eco Science Solutions.
Cannabis Sativa. Inc. (OTCQB: CBDS) recently announced that it entered into an
agreement to acquire the intellectual property for the White Rabbit brand of cannabis
sprays and cannabis mints. The acquisition will include the exclusive and proprietary
product formulations, product mixes, manufacturing methods and branding. The White Rabbit
product line currently consists of fast acting low dose cannabis oral sprays and popular
low dose cannabis mints. Both the spray and the mints are formulated as CBD only, THC only
and CBD/THC blends. Dosage ranges include 2.5mg, 5mg and 10mg tablets and sprays with 1:1
and 20:1 variations of each.
Cara Therapeutics Inc. (NASDAQ: CARA) is developing lead molecules that selectively
modulate peripheral CB receptors without targeting CNS cannabinoid receptors. Peripheral
CB receptor modulators will be initially developed as a novel therapeutic approach for
neuropathic pain, a condition currently without consistently effective therapies. Cara's
most advanced CB compound, CR701, is in preclinical development. Cara's CMO Dr. Joseph
Stauffer said, "Cannabinoid Receptor Agonists like CR701 have the potential to provide
improved pain relief for patients suffering from neuropathic pain."
AXIM Biotechnologies, Inc. (OTCQB: AXIM) focuses on the research, development and
production of cannabis-based pharmaceutical, nutraceutical and cosmetic products. Recently,
the company announced that its product development partner Quay Pharmaceuticals Ltd.
("Quay Pharma") has obtained the relevant licenses from the British Home Office to import
and work with the controlled drugs that are required to continue the development of AXIM's
MedChew Rx(R) pharmaceutical chewing gum's family of products. MedChew Rx(R) - formulated
with 5 mg of cannabidiol (CBD) and 5 mg of tetrahydrocannabinol (THC) - is being developed
as a pharmaceutical drug to treat pain and spasticity associated with multiple sclerosis
(MS).
Please SIGN UP NOW at http://www.FinancialBuzz.com To Receive Alerts on Trending
Financial News from all these companies. "The Latest Buzz in Financial News"
Subscribe Now! Watch us report from NYSE
https://www.youtube.com/FinancialBuzzMedia
Follow us on Twitter for real time Financial News Updates:
https://twitter.com/financialbuzz
Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz
Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz
About FinancialBuzz.com
FinancialBuzz.com, a leading financial news informational web portal designed to
provide the latest trends in Market News, Investing News, Personal Finance, Politics,
Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews.
A pioneer in the financially driven digital space, video production and integration of
social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com
also provides financial news PR dissemination, branding, marketing and advertising for
third parties for corporate news and original content through our unique media platform
that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video
Production, Broadcasting, and Financial Publications.
Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment
advisor or broker-dealer and do not undertake any activities that would require such
registration. The information provided on http://www.FinancialBuzz.com (the "Site") is
either original financial news or paid advertisements provided [exclusively] by our
affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing
firm enters into service agreements with the companies which are the subject to the
articles posted on the Site or other editorials for advertising such companies. We are not
an independent news media provider and therefore do not represent or warrant that the
information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com
receives fees for producing and presenting high quality and sophisticated content on
FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com
does not offer any personal opinions as we purely incorporate public market research along
with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates
financial or corporate news through our unique financial newswire and media platform. We
also do not include any personal opinions or commentary. For this release,
FinancialBuzz.com expects to be compensated three thousand dollars for financial news
dissemination and pr services by chineseInvestors.com inc. Our fees may be either a flat
cash sum or negotiated number of securities of the companies featured on this site, or a
combination thereof. The securities are commonly paid in segments, of which a portion is
received upon engagement and the balance is paid on or near the conclusion of the
engagement. FinancialBuzz.com has signed a two year agreement with chineseinvestors.com
inc. for one hundred thousand restricted common shares for continued financial news
dissemination and pr services. FinancialBuzz.com will always disclose any compensation in
securities or cash payments for financial news PR advertising. FinancialBuzz.com does not
undertake to update any of the information on the Site or continue to post information
about any companies the information contained herein is not intended to be used as the
basis for investment decisions and should not be considered as investment advice or a
recommendation. The information contained herein is not an offer or solicitation to buy,
hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible
for any gains or losses that result from the opinions expressed on the Site, company
profiles, quotations or in other materials or presentations that it publishes
electronically or in print. Investors accept full responsibility for any and all of their
investment decisions based on their own independent research and evaluation of their own
investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing
this website and any pages thereof, you agree to be bound by the Terms of Use and Privacy
Policy, as may be amended from time to time. None of the content issued by
FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell
any particular security, pursue a particular investment strategy or that any security is
suitable for any investor. This publication is provided by FinancialBuzz.com. Each
investor is solely responsible for determining whether a particular security or investment
strategy is suitable based on their objectives, other securities holdings, financial
situation needs, and tax status. You agree to consult with your investment advisor, tax
and legal consultant before making any investment decisions. We make no representations as
to the completeness, accuracy or timeless of the material provided. All materials are
subject to change without notice. Information is obtained from sources believed to be
reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer,
disclosure and Terms of Use. Please visit: http://www.financialbuzz.com
For further information:
Media Contact:
info@financialbuzz.com
+1-877-601-1879
Url: http://www.FinancialBuzz.com
SOURCE FinancialBuzz.com